Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Patterson

Showing results (211-220 of 277) with videos related to

Pageof 28
Sort By:
Clinical and Translational Radiation Oncology|February 9, 2019
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trialsLinda Spiegelberg, Ruud Houben, Raymon Niemans, et al.
Biochemical Pharmacology|October 23, 2004
Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugsRoger M Phillips, Mohammed Jaffar, Derek J Maitland, et al.
BMC Medical Informatics and Decision Making|March 13, 2022
Clinician documentation of patient centered care in the electronic health recordJorie M Butler, Bryan Gibson, Olga V Patterson, et al.
Cancer Gene Therapy|November 27, 2021
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411<sup>NTR</sup> leading to therapeutic benefitDean C Singleton, Alexandra M Mowday, Chris P Guise, et al.
Journal of Medicinal Chemistry|January 9, 2004
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamineMichael P Hay, Frederik B Pruijn, Swarna A Gamage, et al.
Journal of Medicinal Chemistry|February 6, 2026
Structure-Based Design of 4-(1-Methyl-1<i>H</i>-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective InhibitorsWenjian Zhu, Xiaojuan Chen, Xiaofei Li, et al.
Organic & Biomolecular Chemistry|April 17, 2014
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000Robert F Anderson, Pooja Yadav, Deepa Patel, et al.
Cell Chemical Biology|March 7, 2017
Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene TherapyJanine N Copp, Alexandra M Mowday, Elsie M Williams, et al.
The Biochemical Journal|October 4, 2015
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utilityElsie M Williams, Rory F Little, Alexandra M Mowday, et al.
Analytical Chemistry|December 20, 2016
Virus-Enabled Biosensor for Human Serum AlbuminAlana F Ogata, Joshua M Edgar, Sudipta Majumdar, et al.
Pageof 28

Showing results (211-220 of 277) with videos related to

Sort By:
Pageof 28
Clinical and Translational Radiation Oncology|February 9, 2019
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trialsLinda Spiegelberg, Ruud Houben, Raymon Niemans, et al.
Biochemical Pharmacology|October 23, 2004
Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugsRoger M Phillips, Mohammed Jaffar, Derek J Maitland, et al.
BMC Medical Informatics and Decision Making|March 13, 2022
Clinician documentation of patient centered care in the electronic health recordJorie M Butler, Bryan Gibson, Olga V Patterson, et al.
Cancer Gene Therapy|November 27, 2021
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411<sup>NTR</sup> leading to therapeutic benefitDean C Singleton, Alexandra M Mowday, Chris P Guise, et al.
Journal of Medicinal Chemistry|January 9, 2004
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamineMichael P Hay, Frederik B Pruijn, Swarna A Gamage, et al.
Journal of Medicinal Chemistry|February 6, 2026
Structure-Based Design of 4-(1-Methyl-1<i>H</i>-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective InhibitorsWenjian Zhu, Xiaojuan Chen, Xiaofei Li, et al.
Organic & Biomolecular Chemistry|April 17, 2014
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000Robert F Anderson, Pooja Yadav, Deepa Patel, et al.
Cell Chemical Biology|March 7, 2017
Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene TherapyJanine N Copp, Alexandra M Mowday, Elsie M Williams, et al.
The Biochemical Journal|October 4, 2015
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utilityElsie M Williams, Rory F Little, Alexandra M Mowday, et al.
Analytical Chemistry|December 20, 2016
Virus-Enabled Biosensor for Human Serum AlbuminAlana F Ogata, Joshua M Edgar, Sudipta Majumdar, et al.
Pageof 28